[CAS NO. 1383816-29-2] Tropifexor (LJN452)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1383816-29-2]
Store
Catalog
SLK-S8733
Brand
Selleck
CAS
1383816-29-2
DESCRIPTION [1383816-29-2]
Overview
| MDL | MFCD31693060 |
|---|---|
| Molecular Weight | 603.58 |
| Molecular Formula | C29H25F4N3O5S |
| SMILES | O(CC=1C(=NOC1C2CC2)C3=C(OC(F)(F)F)C=CC=C3)[C@@H]4C[C@H]5N([C@@H](C4)CC5)C6=NC=7C(S6)=CC(C(O)=O)=CC7F |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6568 mL | 8.2839 mL | 16.5678 mL |
| 5 mM | 0.3314 mL | 1.6568 mL | 3.3136 mL |
| 10 mM | 0.1657 mL | 0.8284 mL | 1.6568 mL |
| 50 mM | 0.0331 mL | 0.1657 mL | 0.3314 mL |
Description
Tropifexor (LJN452) is a novel and highly potent agonist of with EC50 of 0.2 nM in HTRF assay. It shows no significant off-target activity against a broad panel of enzyme, ion channel, nuclear receptor, and GPCR (>10000-fold selectivity for FXR).
Targets
| FXR [1] (HTRF assay) |
| 0.2 nM(EC50) |
In vitro
LJN-452 in in vitro pharmacological studies has shown to be a potent human FXR agonist with > 30,000-fold selectivity over other nuclear receptors. LJN-452 could increases BSEP and SHP expression in primary human hepatocyte.
References
Synonyms
6-Benzothiazolecarboxylic acid, 2-[(3-endo)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-
2-[(3-endo)-3-[[5-Cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-6-benzothiazolecarboxylic acid
Tropifexor
LJN 452
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.